Panniculitis in Patients Undergoing Treatment With the Bruton Tyrosine Kinase Inhibitor Ibrutinib for Lymphoid Leukemias Ibrutinib is an oral inhibitor of Bruton tyrosine kinase (BTK) withmarked activity in several B-cell malignant neoplasms.1 Commonly reported adverse events include diarrhea, infection, fatigue, arthralgias, pyrexia, hypertension, and neutropenia.2 Grade 1 and 2 rashes have be...

The BTK protein is a 77 kDa protein of 659 amino acids. Translation of the BTK transcript starts at the ATG site that is located in exon 2 and ends in exon 19. The BTK protein is composed of an N-terminal Pleckstrin homology (PH) domain followed three protein interacting domains: Tec homology (TH) region, Src homology 3 (SH3) domain and SH2 domain. A tyrosine-kinase catalytic domain is located ...

Title: Leukemia/Lymphoma-Related Factor (LRF) Regulates Oligodendrocyte Lineage Cell Differentiation in the Developing CNS

Bruton tyrosine kinase (BTK) is a critical effector molecule for B cell development and plays a major role in lymphoma genesis. Ibrutinib is the first-generation BTK inhibitor. Ibrutinib has off-target effects on EGFR, ITK, and Tec family kinases, which explains the untoward effects of ibrutinib. Resistance to ibrutinib was also reported. The C481S mutation in the BTK kinase domain was reported...

Ibrutinib, an oral small molecule inhibitor of Bruton tyrosine kinase (BTK), is approved for all patients with chronic lymphocytic leukemia (CLL) and Waldenström macroglobulinema (WM) and as a second-line agent for patients with mantle cell lymphoma (MCL).[1] Ibrutinib selectively and irreversibly inhibits BTK within B lymphocytes to block constitutively activated intracellular signaling pathwa...

Intravenous immunoglobulin (IVIg) therapy may be considered medically necessary for the following indications.  Immunodeficiency States—patients with Primary Immunodeficiencies, including o Congenital agammaglobulinemia o Hypogammaglobulinemia o Common variable immunodeficiency o Severe combined immunodeficiency (SCID) o Wiskott-Aldrich syndrome o X-linked agammaglobulinemia (Bruton agammaglob...